Blood disorders
Lymphoma in Changsha
长沙 淋巴瘤
5 hospitals in Changsha
Order: papers led on lymphoma, 2021–2025, then A–Z. Research activity, not a rating of care.
Only hospitals listed for lymphoma: those with enough papers or registered trials on it in the records this site uses. Other hospitals in Changsha may also treat it. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first.
- 15 papers ledNo open trial led
- 13 papers ledNo open trial led
- 12 papers ledNo open trial led
- 7 papers ledNo open trial led
- 0 papers led
Lymphoma in every city Changsha on the disease page, with the national map
open trials on lymphoma with a hospital in Changsha
Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 18 Nov 2026, with a listed hospital in Changsha as lead sponsor or study site. 1 of them are led by a hospital in Changsha. Check the registry for the current status. Whether someone can take part is decided by the study team.
Only trials registered on ClinicalTrials.gov are counted. Trials registered only in China’s own registry (ChiCTR) are not.
- RecruitingA Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Phase
- Phase 4
- Started
- 2026-03
- Posted
- Registry
- NCT07218341
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Lanzhou, Nanchang, Shanghai, Tianjin, Urumqi, Xuzhou, Zhengzhou
- RecruitingA Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
- Phase
- Phase 3
- Started
- 2026-03
- Posted
- Registry
- NCT07409428
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 42 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Quanzhou, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Xuzhou, Zhengzhou
- RecruitingExploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07441993
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 11 listed hospitals as study sitesBeijing, Changchun, Changsha, Guangzhou, Jinan, Nanchang, Nantong, Tianjin, Wuhan, Zhengzhou
- RecruitingClinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma
- Phase
- Phase 2
- Started
- 2025-03
- Posted
- Registry
- NCT06854445
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesChangsha, Dalian, Hangzhou, Harbin, Jinan, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Shijiazhuang, Suzhou, Taiyuan, Wuhan, Wuhu, Xi'an, Xiamen, Zhengzhou
- RecruitingNewly-diagnosed Pediatric T-cell ALL Protocol
- Phase
- Phase 2/Phase 3
- Started
- 2025-03
- Posted
- Registry
- NCT06855810
Age 1 month to 18 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 13 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Qingdao, Shanghai, Tianjin, Wuhan
- RecruitingA Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Phase
- Phase 3
- Started
- 2025-06
- Posted
- Registry
- NCT06943872
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hohhot, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Wuxi, Xiamen, Yangzhou
- RecruitingA Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Phase
- Phase 3
- Started
- 2025-09
- Posted
- Registry
- NCT06973187
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Dalian, Fuzhou, Harbin, Lanzhou, Luzhou, Nanchang, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Wenzhou, Wuhan, Xi'an, Xining, Xuzhou, Zhengzhou
- RecruitingDZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)
- Phase
- Phase 1/Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07059650
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Linyi, Taiyuan, Wuhan, Xi'an, Zhengzhou
- RecruitingA Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
- Phase
- Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07082686
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Tianjin, Urumqi, Wuhan, Xi'an, Zhengzhou
- RecruitingA Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-07
- Posted
- Registry
- NCT07124936
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Kunming, Nanchang, Nanning, Shenyang, Suzhou, Taiyuan, Wuhan, Xi'an, Zhengzhou
- RecruitingA Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07154264
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Changzhou, Chengdu, Guangzhou, Hangzhou, Hefei, Nanchang, Nantong, Shenyang, Wuhan, Yichang, Zhengzhou
- RecruitingA Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
- Phase
- Phase 2
- Started
- 2025-11
- Posted
- Registry
- NCT07189065
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Wuhan, Xiamen, Xuzhou, Zhengzhou
- RecruitingA Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas
- Phase
- Phase 1
- Started
- 2024-01
- Posted
- Registry
- NCT06219356
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Hangzhou, Nanchang, Shanghai, Shenyang, Taiyuan, Wuhan, Xiamen, Zhengzhou
- RecruitingA Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
- Phase
- Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT06363994
Age 60 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Luoyang, Nanchang, Nanjing, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Zhengzhou
- RecruitingICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
- Phase
- Phase 2/Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT06378138
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 43 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Huai'an, Jinan, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Yichang, Zhengzhou, Zunyi
- RecruitingEvaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Phase
- Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT06521255
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Nanchang, Shanghai, Suzhou, Tianjin, Urumqi, Wenzhou, Wuhan, Zhengzhou
- RecruitingA Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma
- Phase
- Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT06566586
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesChangsha, Guangzhou, Harbin, Hohhot, Lanzhou, Luzhou, Nanchang, Nanning, Shanghai, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Zhengzhou
- RecruitingA Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
- Phase
- Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT07234162
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Linyi, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingClinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2023-03
- Posted
- Registry
- NCT05768529
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesChangsha, Shanghai, Suzhou
- RecruitingEfficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
- Phase
- Phase 3
- Started
- 2023-12
- Posted
- Registry
- NCT06082102
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Dalian, Guangzhou, Hangzhou, Nanchang, Qingdao, Shanghai, Shenyang, Wuhan, Xi'an, Yantai, Zhengzhou
- RecruitingA Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Phase
- Phase 3
- Started
- 2023-12
- Posted
- Registry
- NCT06136559
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Haikou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Taiyuan, Tianjin, Urumqi, Wuhan, Xuzhou, Zhengzhou
- RecruitingA Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Phase
- Phase 3
- Started
- 2022-07
- Posted
- Registry
- NCT05254743
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChangsha, Guangzhou, Haikou, Hangzhou, Hefei, Nanchang, Nanning, Shanghai, Tianjin, Urumqi, Wuhan
- RecruitingTreatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
- Phase
- Phase 1/Phase 2
- Started
- 2022-05
- Posted
- Registry
- NCT05294731
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Suzhou, Taiyuan, Wenzhou, Wuhan, Zhengzhou
- RecruitingEfficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
- Phase
- Phase 2
- Started
- 2021-04
- Posted
- Registry
- NCT04728893
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Tianjin, Wuhan, Xuzhou, Zhengzhou
- RecruitingEvaluate the Safety and Clinical Activity of HH2853
- Phase
- Phase 1/Phase 2
- Started
- 2020-09
- Posted
- Registry
- NCT04390737
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Zhengzhou
- RecruitingStudy of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
- Phase
- Phase 1/Phase 2
- Started
- 2020-08
- Posted
- Registry
- NCT04494503
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Chongqing, Guangzhou, Guiyang, Hangzhou, Nanchang, Nanjing, Nanning, Shanghai, Shijiazhuang, Suzhou, Tianjin, Wuhan
- RecruitingInternational Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma
- Phase
- Phase 3
- Started
- 2019-08
- Posted
- Registry
- NCT04043494
Age Not stated to 18 years (registered criteria)
Led by University HospitalChangsha
- RecruitingA Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
- Phase
- Phase 1
- Started
- 2018-04
- Posted
- Registry
- NCT03460977
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChangsha, Chengdu, Guangzhou, Nanjing, Wenzhou
- Not yet recruitingBirelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19)
- Phase
- Phase 2/Phase 3
- Started
- 2026-09
- Posted
- Registry
- NCT07712588
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesChangsha, Chongqing, Harbin, Shanghai
- Not yet recruitingA Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).
- Phase
- Phase 3
- Started
- 2026-10
- Posted
- Registry
- NCT07784101
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Nanjing, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xi'an, Zhengzhou
- Not yet recruitingOrelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone Lymphoma
- Phase
- Phase 3
- Started
- 2026-10
- Posted
- Registry
- NCT07896590
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 40 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Zhengzhou
- Not yet recruitingBR Combined With OR in Treatment-naïve Marginal Zone Lymphoma
- Phase
- Phase 2
- Started
- 2025-07
- Posted
- Registry
- NCT07008053
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & Hospital; 5 listed hospitals as study sitesChangsha, Fuzhou, Jinan, Qingdao, Shijiazhuang, Tianjin
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
Disease research in Changsha
Each number is papers led on that disease, 2021–2025. “Open” counts open trials the hospital leads. Hospitals A–Z; this is not a ranking.
A blank cell means no papers or trials were found in these records. It does not mean the hospital does not treat that disease.
| Cancer | Blood disorders | Other diseases | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospital | Nasopharyngeal carcinoma | Oesophageal squamous cell carcinoma | Hepatocellular carcinoma | Stomach cancer | Lung cancer | Pancreatic cancer | Breast cancer | Glioma | Hepatoblastoma | Retinoblastoma | Chordoma | Osteosarcoma | Gastrointestinal stromal tumour | Neuroblastoma | Ewing sarcoma | Multiple myeloma | B-cell acute lymphoblastic leukaemia | Aplastic anaemia | Haemophagocytic lymphohistiocytosis | Lymphoma | Beta thalassaemia | Haemophilia A | Atypical haemolytic uraemic syndrome | Thrombotic thrombocytopenic purpura | Fanconi anaemia | Neuromyelitis optica spectrum disorder | IgG4-related disease | Myasthenia gravis | Moyamoya disease | Wilson disease | Biliary atresia | Coronary heart disease | Congenital heart disease | Scoliosis | Anti-NMDA receptor encephalitis | Takayasu arteritis | Hepatic echinococcosis | Idiopathic pulmonary fibrosis | Lymphangioleiomyomatosis | Amyotrophic lateral sclerosis | Spinal muscular atrophy | Fabry disease | Pompe disease | Duchenne muscular dystrophy | Behçet disease | Alport syndrome | IgA nephropathy | Gaucher disease | Niemann–Pick disease type C | Osteogenesis imperfecta | Primary biliary cholangitis | Primary sclerosing cholangitis | Congenital diaphragmatic hernia | Hirschsprung disease | Inherited epidermolysis bullosa | Hereditary angioedema | Familial adenomatous polyposis | Leber hereditary optic neuropathy | Majeed syndrome | NGLY1 deficiency | ISG15 deficiency | Shortlist |
| Affiliated Changsha Central Hospital, University of South China南华大学附属长沙中心医院 | 3 | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Affiliated XiangTan Central Hospital of Hunan University湘潭市中心医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Changsha Central Hospital长沙市中心医院 | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Changsha Hospital长沙市妇幼保健院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Changsha Hospital, Hunan Normal University长沙市第四医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Changsha Taihe Hospital长沙泰和医院 | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| ChangSha Third Hospital长沙市第三医院 | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Child Health Care Hospital | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 19 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| First Hospital of Hunan University of Chinese Medicine湖南中医药大学第一附属医院 | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Genetic Hospital中信湘雅生殖与遗传专科医院 | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 3 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Hunan Aerospace Hospital湖南航天医院 | none | none | none | none | none | none | none | none | none | none | 1 | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Hunan Cancer Hospital湖南省肿瘤医院 | 532 open | 71 open | 161 open | 252 open | 12028 open | 31 open | 549 open | 20 | none | none | 1 | 8 | none | none | 1 | 0 | none | none | none | 7 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Hunan Chest Hospital湖南省胸科医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Hunan Children's Hospital湖南省儿童医院 | none | none | none | none | none | none | none | none | 3 | none | none | 2 | none | 6 | none | none | 0 | none | 9 | none | none | 0 | none | none | none | none | none | 2 | none | none | 2 | none | 6 | none | 1 | 0 | 1 | none | none | none | 1 | 0 | none | 3 | none | 0 | 0 | none | none | none | none | none | none | 4 | none | none | none | none | none | none | none | |
| Hunan Jiahui Genetics Hospital湖南家辉遗传专科医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 3 | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | |
| Hunan Provincal Tumor Hospital | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Hunan Provincial Hospital湖南省中西医结合医院 (湖南省中医药研究院附属医院) | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Hunan Provincial People's Hospital湖南省人民医院(湖南师范大学附属第一医院) | 1 | none | 50 | none | 29 | 21 | none | none | 1 | 1 | none | 12 | 1 | 2 | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | 4 | 4 | 2 | none | none | none | 3 | none | none | none | none | none | none | none | none | 1 | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | |
| Second Xiangya Hospital中南大学湘雅二医院 | 25 | 6 | 55 | 32 | 14011 open | 19 | 72 | 20 | none | 1 | 2 | 43 | 4 | 5 | 1 | 14 | 3 | 6 | 2 | 13 | 2 | 1 | 1 | 1 | 5 | 7 | 1 | 6 | none | 7 | none | 36 | 40 | 5 | 3 | 5 | none | 18 | 3 | 1 | none | none | none | 1 | 1 | none | 14 | none | none | 0 | 0 | none | none | none | none | none | 1 | none | none | none | none | |
| Third Xiangya Hospital中南大学湘雅三医院 | 19 | none | 41 | 17 | 361 open | 221 open | 36 | 14 | none | 1 | 1 | 24 | none | 2 | none | 19 | 2 | none | 6 | 12 | none | 0 | none | 1 | none | none | none | 3 | none | none | none | 9 | 3 | none | none | none | none | 12 | none | 5 | none | none | 0 | none | 1 | 0 | 4 | none | none | 0 | none | none | none | none | none | none | none | 0 | none | none | none | |
| University Hospital | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 01 open | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Xiangya Hospital中南大学湘雅医院 | 63 | 8 | 1193 open | 35 | 1832 open | 261 open | 831 open | 1581 open | 5 | 2 | 1 | 15 | 41 open | 4 | 1 | 8 | 4 | 3 | 1 | 15 | 1 | 1 | 0 | 2 | 1 | 5 | 1 | 20 | 6 | none | none | 25 | 10 | 32 | 2 | 1 | none | 4 | none | 23 | 2 | 0 | 0 | 3 | 1 | 0 | 4 | none | none | 1 | 0 | 1 | none | none | none | none | 0 | none | none | none | none | |
| Xiangya Stomatological Hospital中南大学湘雅口腔医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | |
Column labels are short names. Choose one to open that disease in Changsha.
- Nasopharyngeal carcinoma 532 open
- Oesophageal squamous cell carcinoma 71 open
- Hepatocellular carcinoma 161 open
- Stomach cancer 252 open
- Lung cancer 12028 open
- Pancreatic cancer 31 open
- Breast cancer 549 open
- Glioma 20
- Chordoma 1
- Osteosarcoma 8
- Ewing sarcoma 1
- Multiple myeloma 0
- Lymphoma 7
- Idiopathic pulmonary fibrosis 0
- IgA nephropathy 1
- Hepatoblastoma 3
- Osteosarcoma 2
- Neuroblastoma 6
- B-cell acute lymphoblastic leukaemia 0
- Haemophagocytic lymphohistiocytosis 9
- Haemophilia A 0
- Myasthenia gravis 2
- Biliary atresia 2
- Congenital heart disease 6
- Anti-NMDA receptor encephalitis 1
- Takayasu arteritis 0
- Hepatic echinococcosis 1
- Spinal muscular atrophy 1
- Fabry disease 0
- Duchenne muscular dystrophy 3
- Alport syndrome 0
- IgA nephropathy 0
- Hirschsprung disease 4
- Nasopharyngeal carcinoma 1
- Hepatocellular carcinoma 50
- Lung cancer 29
- Pancreatic cancer 21
- Hepatoblastoma 1
- Retinoblastoma 1
- Osteosarcoma 12
- Gastrointestinal stromal tumour 1
- Neuroblastoma 2
- Thrombotic thrombocytopenic purpura 0
- Coronary heart disease 4
- Congenital heart disease 4
- Scoliosis 2
- Idiopathic pulmonary fibrosis 3
- IgA nephropathy 1
- Primary sclerosing cholangitis 1
- Nasopharyngeal carcinoma 25
- Oesophageal squamous cell carcinoma 6
- Hepatocellular carcinoma 55
- Stomach cancer 32
- Lung cancer 14011 open
- Pancreatic cancer 19
- Breast cancer 72
- Glioma 20
- Retinoblastoma 1
- Chordoma 2
- Osteosarcoma 43
- Gastrointestinal stromal tumour 4
- Neuroblastoma 5
- Ewing sarcoma 1
- Multiple myeloma 14
- B-cell acute lymphoblastic leukaemia 3
- Aplastic anaemia 6
- Haemophagocytic lymphohistiocytosis 2
- Lymphoma 13
- Beta thalassaemia 2
- Haemophilia A 1
- Atypical haemolytic uraemic syndrome 1
- Thrombotic thrombocytopenic purpura 1
- Fanconi anaemia 5
- Neuromyelitis optica spectrum disorder 7
- IgG4-related disease 1
- Myasthenia gravis 6
- Wilson disease 7
- Coronary heart disease 36
- Congenital heart disease 40
- Scoliosis 5
- Anti-NMDA receptor encephalitis 3
- Takayasu arteritis 5
- Idiopathic pulmonary fibrosis 18
- Lymphangioleiomyomatosis 3
- Amyotrophic lateral sclerosis 1
- Duchenne muscular dystrophy 1
- Behçet disease 1
- IgA nephropathy 14
- Osteogenesis imperfecta 0
- Primary biliary cholangitis 0
- Familial adenomatous polyposis 1
- Nasopharyngeal carcinoma 19
- Hepatocellular carcinoma 41
- Stomach cancer 17
- Lung cancer 361 open
- Pancreatic cancer 221 open
- Breast cancer 36
- Glioma 14
- Retinoblastoma 1
- Chordoma 1
- Osteosarcoma 24
- Neuroblastoma 2
- Multiple myeloma 19
- B-cell acute lymphoblastic leukaemia 2
- Haemophagocytic lymphohistiocytosis 6
- Lymphoma 12
- Haemophilia A 0
- Thrombotic thrombocytopenic purpura 1
- Myasthenia gravis 3
- Coronary heart disease 9
- Congenital heart disease 3
- Idiopathic pulmonary fibrosis 12
- Amyotrophic lateral sclerosis 5
- Pompe disease 0
- Behçet disease 1
- Alport syndrome 0
- IgA nephropathy 4
- Osteogenesis imperfecta 0
- Leber hereditary optic neuropathy 0
- Nasopharyngeal carcinoma 63
- Oesophageal squamous cell carcinoma 8
- Hepatocellular carcinoma 1193 open
- Stomach cancer 35
- Lung cancer 1832 open
- Pancreatic cancer 261 open
- Breast cancer 831 open
- Glioma 1581 open
- Hepatoblastoma 5
- Retinoblastoma 2
- Chordoma 1
- Osteosarcoma 15
- Gastrointestinal stromal tumour 41 open
- Neuroblastoma 4
- Ewing sarcoma 1
- Multiple myeloma 8
- B-cell acute lymphoblastic leukaemia 4
- Aplastic anaemia 3
- Haemophagocytic lymphohistiocytosis 1
- Lymphoma 15
- Beta thalassaemia 1
- Haemophilia A 1
- Atypical haemolytic uraemic syndrome 0
- Thrombotic thrombocytopenic purpura 2
- Fanconi anaemia 1
- Neuromyelitis optica spectrum disorder 5
- IgG4-related disease 1
- Myasthenia gravis 20
- Moyamoya disease 6
- Coronary heart disease 25
- Congenital heart disease 10
- Scoliosis 32
- Anti-NMDA receptor encephalitis 2
- Takayasu arteritis 1
- Idiopathic pulmonary fibrosis 4
- Amyotrophic lateral sclerosis 23
- Spinal muscular atrophy 2
- Fabry disease 0
- Pompe disease 0
- Duchenne muscular dystrophy 3
- Behçet disease 1
- Alport syndrome 0
- IgA nephropathy 4
- Osteogenesis imperfecta 1
- Primary biliary cholangitis 0
- Primary sclerosing cholangitis 1
- Familial adenomatous polyposis 0
Other cities nearby
Straight-line distance from the city centre; counts are hospitals listed for lymphoma.
Counts are listed hospitals only, not every hospital in each city.
Where these numbers come from
Papers
English-language PubMed papers, 2021–2025, where the first or last author lists the hospital first. Definitions
Trials
ClinicalTrials.gov records with the hospital as lead sponsor or site, as of 8 Nov 2026. Search Changsha on ClinicalTrials.gov
Locations
Locations are shown at city centres. Check the hospital’s website for its address.